CO6630107A2 - Formas de dosificación sólidas orales con dosis muy bajas para hrt - Google Patents

Formas de dosificación sólidas orales con dosis muy bajas para hrt

Info

Publication number
CO6630107A2
CO6630107A2 CO12180903A CO12180903A CO6630107A2 CO 6630107 A2 CO6630107 A2 CO 6630107A2 CO 12180903 A CO12180903 A CO 12180903A CO 12180903 A CO12180903 A CO 12180903A CO 6630107 A2 CO6630107 A2 CO 6630107A2
Authority
CO
Colombia
Prior art keywords
hrt
low doses
dosage form
dosage forms
oral dosage
Prior art date
Application number
CO12180903A
Other languages
English (en)
Inventor
Stephan Mletzko
Rolf Schurmann
Kerstin Gude
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CO6630107A2 publication Critical patent/CO6630107A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma de dosificación con una dosis muy baja para la terapia de reemplazo de hormonas (HRT), más particularmente una forma de dosificación sólida oral que comprende aproximadamente 0,5 mg de estradiol (que se abrevie “E2”) y aproximadamente 0,25 mg de drospirenona (que se abrevia “DRSP”), así como al menos un excipiente farmacéuticamente aceptable. A pesar de las dosis muy bajas de E2 y de DRSP, sorprendentemente se ha descubierto que una proporción elevada de las mujeres que sufren calores moderados a severos de hecho responden a este tratamiento. Por consiguiente, la forma de dosificación de la invención puede usarse como HRT de mantenimiento o puede usarse cuando ye se ha iniciado la HRT.
CO12180903A 2010-04-15 2012-10-12 Formas de dosificación sólidas orales con dosis muy bajas para hrt CO6630107A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10160072 2010-04-15

Publications (1)

Publication Number Publication Date
CO6630107A2 true CO6630107A2 (es) 2013-03-01

Family

ID=44260074

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12180903A CO6630107A2 (es) 2010-04-15 2012-10-12 Formas de dosificación sólidas orales con dosis muy bajas para hrt

Country Status (18)

Country Link
US (3) US20130137664A1 (es)
EP (1) EP2558063B1 (es)
JP (1) JP5820465B2 (es)
KR (2) KR20180018827A (es)
CN (1) CN102985070A (es)
AR (1) AR080912A1 (es)
AU (1) AU2011240102B2 (es)
BR (1) BR112012026115B1 (es)
CA (1) CA2795801C (es)
CO (1) CO6630107A2 (es)
CR (1) CR20120523A (es)
EA (1) EA026095B1 (es)
GT (1) GT201200281A (es)
IL (1) IL222353A0 (es)
MX (1) MX356702B (es)
TW (1) TWI519300B (es)
UY (1) UY33343A (es)
WO (1) WO2011128336A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
ME03728B (me) 2015-06-18 2021-01-20 Estetra Sprl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
SI3310345T1 (sl) 2015-06-18 2021-05-31 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4590569A (en) 1983-10-14 1986-05-20 Navigation Sciences Inc. Navigation system including an integrated electronic chart display
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
EP1380301B1 (en) * 1999-08-31 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and dropirenone for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
DE60113809T2 (de) * 2000-01-18 2006-06-22 Schering Ag Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1406634A1 (en) 2001-07-13 2004-04-14 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
NZ548754A (en) * 2002-04-26 2008-06-30 Schering Aktiengellschaft Treatment of hypertension in women receiving hormone replacement therapy
AU2002368326A1 (en) 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
AU2004275469B2 (en) 2003-09-29 2010-07-15 Novo Nordisk Health Care Ag HRT formulations
WO2005030176A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Improved stability of progestogen formulations
DE602004017045D1 (de) 2003-11-14 2008-11-20 Warner Chilcott Co Inc Graduierte östrogen-kontrazeptiva
UY29185A1 (es) * 2004-11-02 2006-05-31 Schering Ag Formas de dosificación oral sólidas que contienen una dosis baja de estradiol
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8475838B2 (en) 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
BRPI0810049A2 (pt) 2007-04-05 2015-05-05 Bayer Schering Pharma Ag Regime de drospirenona/17beta-estradiol, produto de combinação farmacêutica e kit para realizar esse regime
US20090045024A1 (en) 2007-08-13 2009-02-19 Means Industries, Inc. Overrunning Radial Coupling Assembly Having Dual Bearing Support
WO2009112232A2 (en) * 2008-03-10 2009-09-17 Vladimir Hanes New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009138224A1 (en) 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone

Also Published As

Publication number Publication date
AU2011240102B2 (en) 2015-07-23
GT201200281A (es) 2014-11-26
MX2012012026A (es) 2013-01-22
CA2795801A1 (en) 2011-10-20
US20110275601A1 (en) 2011-11-10
CN102985070A (zh) 2013-03-20
EA201201403A1 (ru) 2013-04-30
US8906890B2 (en) 2014-12-09
JP5820465B2 (ja) 2015-11-24
AU2011240102A1 (en) 2012-11-01
EP2558063B1 (en) 2021-09-29
JP2013523860A (ja) 2013-06-17
EA026095B1 (ru) 2017-03-31
MX356702B (es) 2018-06-11
EP2558063A1 (en) 2013-02-20
US9592245B2 (en) 2017-03-14
UY33343A (es) 2011-12-01
AR080912A1 (es) 2012-05-16
BR112012026115A2 (pt) 2016-06-28
TW201204368A (en) 2012-02-01
KR20130097073A (ko) 2013-09-02
IL222353A0 (en) 2012-12-31
US20150094287A1 (en) 2015-04-02
CA2795801C (en) 2018-05-29
WO2011128336A1 (en) 2011-10-20
BR112012026115B1 (pt) 2019-12-24
US20130137664A1 (en) 2013-05-30
CR20120523A (es) 2013-01-09
TWI519300B (zh) 2016-02-01
KR20180018827A (ko) 2018-02-21

Similar Documents

Publication Publication Date Title
CO6630107A2 (es) Formas de dosificación sólidas orales con dosis muy bajas para hrt
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
DOP2014000124A (es) Derivados de 6,7-dihidro-5h-benzo[7]anuleno, procesos para su preparación, productos farmacéuticos que comprenden a los mismos y su uso en la preparación de medicamentos
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
PE20160245A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
CL2022000095A1 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
CO6771460A2 (es) Tratamiento de la atrofia vaginal con nueva indicación para la mirra
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
WO2011128337A3 (en) Low-dosed solid oral dosage forms for hrt
MX2015016678A (es) Formulaciones farmaceuticas que comprenden agomelatina en forma de cocristal de agomelatina con un acido organico.
AR067465A1 (es) Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico

Legal Events

Date Code Title Description
FC Application refused